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Glycan-independent binding and 
internalization of human IgM to 
FCMR, its cognate cellular receptor
Katy A. Lloyd1, Jiabin Wang2, Britta C. Urban1, Daniel M. Czajkowsky3 & Richard J. Pleass1
IgM is the first antibody to be produced in immune responses and plays an important role in the 
neutralization of bacteria and viruses. Human IgM is heavily glycosylated, featuring five N-linked 
glycan sites on the μ chain and one on the J-chain. Glycosylation of IgG is known to modulate the 
effector functions of Fcγ receptors. In contrast, little is known about the effect of glycosylation on IgM 
binding to the human Fcμ receptor (hFCMR). In this study, we identify the Cμ4 domain of IgM as the 
target of hFCMR, and show that binding and internalization of IgM by hFCMR is glycan-independent. 
We generated a homology-based structure for hFCMR and used molecular dynamic simulations to 
show how this interaction with IgM may occur. Finally, we reveal an inhibitory function for IgM in the 
proliferation of T cells.
The human Fcμ receptor (hFCMR), also known as Toso or FAIM3, is a high affinity receptor for the Fc portion of 
human immunoglobulin M (hIgM), which is expressed on B cells, T cells (CD4+ and CD8+), and a subset of NK 
cells (CD3−CD56+)1–3. Although the functions of hFCMR are still being resolved, the receptor has been impli-
cated in the homeostasis of IgM in mice4,5. Mice deficient in FCMR have significantly elevated serum levels of 
IgM4,5, and cross-linking of hFCMR on chronic lymphocytic leukaemia (CLL) cells by hIgM results in the rapid 
internalization of hIgM6. Following internalization by hFCMR, hIgM is shuttled through the endocytic pathway 
to lysosomes and degraded6. Although yet to be proven, hFCMR-mediated internalization and degradation of 
IgM-opsonized antigens may be important for cross-presentation by B cells1,6. Alternatively, since natural pol-
yclonal IgM is an important first line defense against bacteria and viruses7, hFCMR could function to transport 
hIgM-opsonized immune-complexes to lysosomes where, depending on antigen, TLR activation may ensue. 
Intriguingly, protein expression and mRNA of hFCMR was reduced in CLL cells following exposure to TLR7 and 
TLR9 agonists (imiquimod and CpG-ODN), suggesting a link between TLR activation and hFCMR expression6.
IgM molecules are heavily glycosylated oligomers containing five N-linked glycosylation sites on each heavy 
chain and one site on the J-chain8. In total, these N-linked glycans constitute approximately 10% of the molecular 
weight of hIgM9. Glycosylation is important for hIgM secretion and its presentation on B cell surfaces8,10,11, yet it 
is unclear whether hIgM glycosylation is required for binding to hFCMR, and what the functional consequences 
of this binding may be. Glycosylation of the Fc region of immunoglobulins plays a pivotal role in facilitating the 
binding to certain high affinity FcRs12. Abrogation of IgG glycosylation by mutating the conserved N-linked 
glycosylation site of IgG (e.g. N297 to N297A by alanine mutagenesis), or by completely removing glycans with 
the peptide N-glycosidase (PNGase) F, are well established strategies to abrogate binding to Fcγ Rs13. Similarily, 
PNGase F-treatment and mutagenesis of the N-linked site Asn394 in IgE, which is homologous to Asn297 in IgG, 
results in reduced binding to the high affinity Fcε receptor (Fcε RI)14,15.
In this study, we investigate the effect of hIgM glycosylation on the binding to hFCMR and its subsequent 
internalization within the cell. Our findings show, surprisingly, that glycosylation of hIgM is not critical for its 
interaction with hFCMR, which we show is dominated by the Cμ 4 domain of hIgM.
Results
The Cμ4 domain of hIgM forms the binding site for human FCMR. To determine the region of 
the IgM molecule critical for interaction with hFCMR, we used a panel of domain-swapped Ab described pre-
viously16–18, in which homologous constant domains are exchanged between human IgA and IgM. The ability 
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of GFP-gated hFCMR-transfected cell lines1 (Fig. 1a) to bind the domain-swapped Ab was analyzed by flow 
cytometry (Fig. 1b). We observed that those Ab that contained only the Cμ 4 domain were able to interact with 
hFCMR. In contrast, no binding was observed with hIgA and only weak binding was seen with the α 1μ 2μ 3α 3 
domain-swap lacking the Cμ 4 domain. This shows that either the Cμ 2 and/or Cμ 3 domains are involved in bind-
ing hFCMR, although their contribution is less important than the Cμ 4 domain.
Human FCMR is an endocytosis receptor for IgM. We next assessed the ability of hFCMR to internalize 
hIgM by flow cytometry. hIgM was rapidly internalized into hFCMR-transfected cell lines, with ~50% reduction 
of hIgM on cell surfaces seen within 5 min of incubation at 37 °C (Fig. 2a,b), and only ~35% hIgM remaining on 
the cell surface after 1 hr (Fig. 2a,b). The loss of hIgM from the surface of non-permeabilized hFCMR-transfected 
cells, coupled with the accumulation of hIgM in the cytoplasm of permeabilized hFCMR-transfected cells, 
following incubations at 37 °C confirmed that hIgM was internalized by hFCMR (Fig. 2c). Furthermore, the 
well-characterised inhibitor of clathrin-dependent endocytosis phenylarsine oxide (PAO) was used to further 
confirm and characterise IgM internalization. hFCMR-transfected cells incubated for 60 min at 37 °C in the 
presence of PAO exhibited reduced IgM internalization when compared to those incubated with DMSO alone 
(Fig. 2d). These results indicate that hFCMR internalizes IgM at least in part by clathrin-dependent mechanisms. 
We next tested if hIgM internalization also occurred in the physiological environment provided by human serum, 
or if other components in human serum affected the uptake of hIgM by hFCMR. There was no significant differ-
ence between the internalization of hIgM provided in serum compared to purified hIgM diluted in physiological 
buffers (P = 0.746, Fig. S1A).
Since immune-complexes (ICs) are known to bind receptors with greater avidity13,19, we next investigated the 
effect of IgM-ICs on binding and internalization by hFCMR. Indeed, heat-aggregated hIgM exhibited enhanced 
binding to hFCMR-transfected cells and was similarly internalized (Fig. 2e).
Since cell lines do not reflect potential hFCMR expression on human cells, we next evaluated the ability of 
lymphocyte subsets known to express hFCMR (Fig. 3a) to bind and internalize hIgM. As shown in Fig. 3b, exog-
enous hIgM bound to and was internalized by B cells, T cells (CD4+ and CD8+), and NK cells, in agreement with 
previous observations1. For T cells, CD8+ subsets exhibited enhanced internalization of hIgM compared to CD4+, 
with ~65% reduction in hIgM surface levels for CD4+ T cells seen within 5 min compared to ~75% reduction for 
CD8+ T cells (Fig. 3b). With NK cells, surface levels of hIgM were reduced by ~85% within 5 min upon incubation 
(Fig. 3b). Furthermore, there was a noticeable reduction of ~50% of cell surface IgM on B cells upon incubation 
with human serum compared to those incubated with media alone (Fig. 3b). We observed enhanced rates of 
hIgM uptake from the surface of all lymphocyte subsets investigated, although the functional consequences of 
this uptake need to be further studied.
De-glycosylation does not affect binding or internalization of IgM by hFCMR. The five N-linked 
glycosylation sites (Asn171, Asn332, Asn395, Asn402, and Asn563) in the μ chain of hIgM are predominantly occu-
pied by complex glycans terminating in sialic acid, galactose, or oligomannose glycans8. As glycosylation of human 
IgG can significantly modulate effector functions via Fcγ Rs, such as antibody-dependent cell cytotoxicity20–22, 
we hypothesized that de-glycosylation of hIgM may also affect interactions with hFCMR.
N-linked glycans were removed from hIgM with PNGase F or neuraminidase (Fig. S2), and the ability of 
de-glycosylated or de-sialylated hIgM to bind hFCMR was investigated. De-glycosylation and de-sialylation of 
IgM was confirmed with Coomassie staining and immunoblotting with either SNA lectin or anti-human IgM 
(Fig. S2B). The de-glycosylation or de-sialylation of hIgM with either PNGase F or neuraminidase respectively 
had no obvious effect on binding or internalization of hIgM by hFCMR-transfected cell lines, when compared to 
non-treated hIgM (Fig. 4a and b, respectively). Intriguingly, de-glycosylation of IgM with PNGase F reduced its 
binding to untransfected cells, whereas neuraminidase-treatment had a lesser effect (Fig. S3). This data suggests 
that the binding of IgM to untransfected cells, although minimal compared to IgM binding to hFCMR–trans-
fected cells, is most likely also owing to scavenging lectin interactions.
Lymphocytes express numerous receptors known to bind glycans, including C-type lectin receptors including 
CD62L, CD33 (Siglec-3), or CD22 (Siglec-2)23–26. Therefore, to rule out the involvement of glycan receptors in 
hIgM internalization by lymphocytes, internalization assays were repeated with de-glycosylated hIgM (Fig. S4). 
There was no difference in the internalization of de-glycosylated hIgM by T cells (CD4+ and CD8+) and B cells, 
when compared to non-treated hIgM (Fig. S4). Together, these results demonstrate that PNGase F or neuramini-
dase susceptible glycan(s), do not likely contribute to the binding or internalization of hIgM by hFCMR.
Molecular dynamic stimulations of the interaction between IgM and hFCMR. To provide struc-
tural insight into how IgM may interact with hFCMR, we evaluated potential binding mechanisms using all-atom 
molecular dynamics (MD) simulations. While there is presently a working atomic model of pentameric IgM27, 
there is currently no structural data available for hFCMR. We thus sought structural homologs of hFCMR using 
Phyre2, a robust web portal for predicting and analyzing protein structures, functions and mutations28,29. Two 
regions of hFCMR were identified that exhibit significant homology to known proteins: one segment (from res-
idues Phe252 to Val272) is homologous to the transmembrane domain of the Erbb2 receptor30 and the other 
segment (from residues Val33 to Gly105) is homologous to many Ig-like domains (Fig. 5a). Two other proteins 
that bind IgM (namely, FCMR and pIgR) also have similar Ig-like regions, and with these proteins, the Ig-like 
regions have been shown to directly contact IgM1,31–35. More specifically, this earlier work demonstrated that this 
interaction occurs via three loops (CDR1, CDR2, and CDR3) at one end of this domain. Thus, we investigated 
possible binding interactions of the analogous end of the Ig-like domain of hFCMR with IgM by MD simulations.
Based on the FACS results (Figs 1b and 4), we evaluated two putative interactions, namely Cμ 2/Cμ 4/hFCMR 
and Cμ 3/Cμ 4/hFCMR (Supplementary Fig. S5 and methods). Following equilibration of these models (entailing 
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~30 ns for each system), we found that the number of residues in close contact within the interaction interface and 
the buried surface area of this interface were both significantly greater in the Cμ 2/Cμ 4/hFCMR model (Fig. S5). 
Figure 1. The Cμ4 domain of IgM binds to human FCMR. (a) Mouse BW5147 T cell lines alone (none) or 
transfected with the retroviral construct containing both human FCMR and GFP cDNAs (FCMR/GFP) were 
incubated with media alone (isotype control; left panels) or media supplemented with mouse anti-hFCMR 
mAb (1 μ g: middle panels), washed and then labeled with anti-mouse IgG-APC to detect hFCMR expression 
by flow cytometry. The binding of human IgM (15 μ g/ml; right panels) to these cell lines was confirmed. 
(b) GFP+ hFCMR-transfected cells were incubated with media supplemented with domain-swap Abs (blue 
trace), hIgM (black trace), or media alone (grey trace) for 1 hr at 4 °C, then washed extensively. Binding of 
Abs was determined by staining with F(ab’)2-anti lambda-RPE and subsequent flow cytometry analysis. Data 
are representative of three repeat experiments. Domain swap antibodies have been previously described in 
detail16–18.
www.nature.com/scientificreports/
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Figure 2. Human FCMR mediates endocytosis of hIgM. (a) To investigate hIgM internalization by FCMR, 
GFP+ hFCMR-transfected cells were incubated with media alone (grey trace) or media supplemented with 
15 μ g/ml purified hIgM for 1 hr at 4 °C. After washing, cells were left at 4 °C (black trace) or incubated at 37 °C 
for the indicated times. Internalization was halted with the addition of ice-cold media, and cells were washed 
extensively to remove unbound IgM. Cells were then labeled with F(ab’)2-anti-human IgM-RPE and analyzed 
by flow cytometry. (b) IgM cell surface levels (geometric MFI) were normalized to time 0. The mean ± SD from 
five experiments are shown. (c) Following incubation at 37 °C, hFCMR-transfected cells were cytospun, fixed 
and permeabilized, and incubated with F(ab’)2-anti-human IgM-RPE for 1 hr. Cells were washed, and labeled 
with DAPI prior to visualization. Red labeling depicts IgM levels (anti-hIgM-RPE); blue colour, nuclei (DAPI); 
and green colour shows hFCMR-transfected cells (GFP). Permeabilization of hFCMR-transfected cells resulted 
in partial quenching of the GFP signal. (d) hFCMR-transfected cells were either left at 4 °C (grey) or incubated 
for 60 min at 37 °C in the presence or PAO (30 μ M, red) or carrier control DMSO (blue). Data shown is one 
of three representative repeat experiments. (e) IgM cell surface levels (GMFI) indicate enhanced binding and 
internalization of heat-aggregated IgM (IgM-IC) to hFCRM-transfected cell lines, when compared to hIgM 
(n = 3).
www.nature.com/scientificreports/
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Figure 3. Internalization of IgM on lymphocyte subsets. (a) Gating strategy for lymphocyte subsets known to 
express hFCMR. PBMCs were labeled with 1 μ M LIVE/DEAD Aqua Dead Cell stain, anti-human CD3-Brilliant 
Violet 421, anti-human CD56-Alexa Fluor 700, anti-human CD8-PerCp, and anti-human CD4-FITC for 1 hr at 
4 °C. To differentiate B cells, LIVE/DEAD stained PBMCs were incubated with anti-human CD3-Brilliant Violet 
421 and anti-human CD19-FITC. Labeled cells were analyzed and gated by flow cytometry. (b) Surface levels 
of IgM (GMFI) on gated lymphocytes incubated with media alone (no IgM) or media supplemented with 10% 
human serum. The mean ± SD of three independent experiments is shown.
www.nature.com/scientificreports/
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In particular, there were 25 residues within close contact (3 Å) in the Cμ 2,4/hFCMR interface but only 18 residues 
in the Cμ 2,3/hFCMR interface. In addition, the area buried within the Cμ 2,4/hFCMR interface is 1352 Å2 but 
only 855 Å2 within the Cμ 2,3/hFCMR interface. This Cμ 2,4/hFCMR interfacial area is comparable to the interfa-
cial areas of many oligomeric proteins36. Hence, this analysis suggests that the interaction of hFCMR with Cμ 2/
Cμ 4 is more energetically favorable than with Cμ 3/Cμ 4.
With this, we performed additional simulations of a model of Cμ 2/Cμ 4/hFCMR (see Methods) to obtain a 
final structure of this interaction (Fig. 5a). Inspection of the Cμ 2,4/hFCMR interface reveals several polar and 
hydrophobic residues that may play a significant role in mediating this interaction (Fig. 5a). In particular, there 
were extensive hydrogen-bonding between side chains and backbone atoms involving Asn422, Leu420, Pro321, 
and His327 in IgM and Pro40, Glu41, Arg83, and Asn85 in hFCMR that surround a hydrophobic pocket consist-
ing of Gly323, Ala325, Leu326 and Ala419 in IgM and Met42, Val44, and Pro82 hFCMR (Fig. 5b). In addition, 
there is also a smaller hydrophobic patch, involving Leu109 in IgM and Ala70 in hFCMR that also appears to 
play a significant role in this interaction (Fig. 5b). We note that the Cμ 4 N-linked glycan at Asn563 is located in 
the tailpiece region that is far from this putative binding interface (Fig. S6), consistent with the observation that 
removal of N-linked glycans does not have a perturbative effect on hFCMR binding (Fig. 4).
hIgM inhibits T cell proliferation. IgM was recently reported to induce potent inhibition of T cell 
responses37. As we showed binding and internalization of IgM by T cells, we wished to determine what effect this 
has, if any, on T cell proliferation. Peripheral blood mononuclear cells (PBMCs) isolated from healthy donors 
were stimulated with phytohemagglutinin (PHA) in the presence or absence of hIgM for 5d at 37 °C. Incubations 
with bovine serum albumin (BSA) were performed in parallel as a negative control. Human IgM strongly inhib-
ited PHA-induced proliferation of CD4+ and CD8+ T cells in a dose-dependent manner (Fig. 6a and b, respec-
tively). Incubations of PBMCs with hIgM or BSA alone did not induce proliferation of T cells (Fig. S7). No 
significant inhibition of CD4+ and CD8+ T cell proliferation was observed with similar concentrations of BSA. 
Together these results show that hIgM can potently inhibit T cell proliferative responses.
Discussion
Previous work has shown that the Fc5μ fragment of IgM comprised mainly of Cμ 3/Cμ 4 domains is involved in 
binding to the hFCMR1, although which domain or amino acid residues within the Fc5μ that make the critical 
Figure 4. Effect of de-glycosylation on FCMR-mediated IgM internalization. PNGase F (a) and 
neuraminidase (b) were used to cleave glycans from IgM molecules. The binding of endoglycosidase-treated 
(green trace) and non-treated (black trace) hIgM to hFCMR-transfected cells is shown as traces in the left 
panels. Internalization of endoglycosidase-treated IgM was also investigated, whereby IgM surface levels 
(GMFI) were normalized to time 0 (right panels). The mean ± SD of three independent repeats is shown.
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contacts with hFCMR remained unidentified. Here, we show that the Cμ 4 domain of IgM makes the major con-
tribution to binding, with only a minor contribution from the Cμ 2 and/or the Cμ 3 domains (Fig. 1b). Other 
receptors for IgM such as hFcα /μ R and pIgR also bind the Cμ 4 domain17,18, although they have a very different 
cellular distribution to the hFCMR.
Since the interaction of IgG with Fcγ Rs is known to be critically dependent on the presence of a N-linked 
glycan at Asn297 in the Cμ 2 domain38, and given the presence of an N-linked glycan in the Cμ 4 domain of hIgM 
at position Asn5638, we investigated if these glycans contributed to the observed binding with hFCMR (Fig. 4). 
In contrast to IgG, removal of glycans from hIgM with PNGase F or neuraminidase had no effect on hFCMR 
binding, although similar treatment of hIgM with PNGase F did significantly reduce interactions with the 
Figure 5. Model of FCMR binding to human IgM. (a) Homology model of the monomeric Ig-like domain 
of hFCMR (left panel). The CDR regions expected to directly contact IgM are shown in stick representation 
(yellow). Final model of the interaction between the Fc domain of hIgM and hFCMR (right panel). (b) Finer 
details of the IgM/FCMR interface. The residues of one protein that are within 3 Å of the other protein for more 
than 75% of the simulations are shown in stick representation. The upper panel shows the hydrophobic residues 
within this interface, and the lower panel shows the polar residues. The hydrophobic, positively charged, 
negatively charged, and polar residues are colored white, blue, red, and orange respectively.
www.nature.com/scientificreports/
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lectin-dependent receptor DC-SIGN39. Similarily, de-glycosylation of human IgA did not affect binding to Fcα 
R (CD89)40,41, suggesting that glycan-dependent mechanisms are not essential for all antibody binding to FcRs.
The hFCMR has been implicated in IgM homeostasis1,4,5, and one study showed receptor cross-linking with 
hIgM promoted the rapid internalization of hIgM and hFCMR into CLL B cells, and transfected HeLa and 
BW5147 cell lines6,42. Here, we confirm and extend these previous observations by showing that hFCMR also pro-
motes the internalization of IgM complexes (heat-aggregated), and importantly, show that hIgM internalization 
by hFCMR was glycan independent. In flow cytometry experiments we observed a significant proportion (~40%) 
of IgM remains on the cell surface while the rest is rapidly internalized. This may occur through heterogeneity of 
IgM forms (presence or absence of J-chain), or to the expression of different FCMR variants and/or localization 
within different domains in the plasma membrane. For example, a FCMR splice variant lacking the transmem-
brane exon has been described that may encode a form of FCMR incapable of internalization1. In this regard, we 
note that for NK cells, the internalization was much more efficient (Fig. 3b), perhaps consistent with a differential 
ability of FCMR to be internalized in different cells.
These results are supported by recent findings that de-sialylated IgM bound to the surface of T cells37. 
However, this same study found that de-sialylated IgM remained on the cell surface following 24 h incubations 
at 37 °C, and only sialylated IgM (IgMh1) was internalized and shuttled to lysosomes37. Although the receptor 
responsible for the internalization was not identified in the study, hFCMR involvement was suggested as it is cur-
rently the only known receptor for IgM expressed on T cells37. We are presently unaware of the reason for these 
observed differences, although differential expression of hFCMR could offer one explanation for the discrepancy. 
The receptor is highly expressed on the transfected cells1, and previous data has shown dispersed expression on T 
cell subsets1. Furthermore, it is still highly likely that in addition to hFCMR, other glycan receptors for IgM will be 
identified on T cells which could potentially bind hIgM. Members of the glycan-binding galectin family associate 
with human T cells43–45, and galectin 9 has been shown to bind to the heavy chain of serum IgM46. Investigating 
the expression of hFCMR, or by performing immunoprecipitations using defined glyco-variants of IgM mole-
cules, could help to clarify whether other receptors are indeed involved in IgM internalization by T cells.
Intriguingly, we also showed that IgM potently inhibits T cell proliferation, whereas there was no intrinsic 
proliferative ability with hIgM alone, supporting the work from previous observations37. This finding strongly 
supports the use of recombinant IgM-based therapies for the treatment of pro-inflammatory conditions, and 
provides a theoretical underpinning for efforts to harness the therapeutic potential of this under-appreciated 
class of antibody. Further work now needs to be done to determine the mechanism by which IgM inhibits T cell 
proliferation.
In conclusion, our findings highlight a critical role for the Cμ 4 domain of IgM in binding hFCMR and show 
that glycans on IgM are not likely involved. This finding is potentially of clinical importance as IgM Fc-fusion pro-
teins are being used to deliver cytotoxic drugs directly to CLL cells via hFCMR47. Given the lack of a requirement 
for IgM glycans in the interaction with hFCMR, these findings suggest that smaller Fc-fusions, encompassing 
only the Cμ 4 domain and lacking sugars, may be more easily manufactured by prokaryotic expression systems 
for optimal pharmaceutical preparations. As glycans also impede crystallization, our work suggests that it may 
therefore be possible to remove the glycans from IgM in order to more readily generate co-crystals with hFCMR 
in structural studies.
Figure 6. IgM inhibits T cell proliferation. Various concentrations of IgM or BSA were incubated with  
5 μ g/ml PHA for 30 min at 4 °C, prior to five day incubation with CellTrace Violet-labeled PBMCs at 37 °C. PHA 
alone was used as a positive control and media only as a negative control (grey trace, lower panels). Percentage 
of proliferating CD4+ and CD8+ T cells (panels A and B, respectively) were normalized to samples incubated 
with PHA and BSA (upper panels). Data are represented as mean ± SD of two independent experiments.
www.nature.com/scientificreports/
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Materials and Methods
Antibodies and reagents. Anti-human CD4-FITC, anti-human CD19-FITC, goat F(ab’)2 anti-human-
IgM-RPE, and goat F(ab’)2 anti-human-lambda-RPE were from SouthernBiotech. Anti-human CD8-PerCp 
and anti-human CD56-Alexa-Fluor 700 were purchased from Biolegend. CellTrace Violet Cell Proliferation 
Kit, LIVE/DEAD Fixable Aqua Dead cell stain kit and anti-human CD3 Brilliant Violet 421 were from Life 
Technologies, and anti-human FAIM3 (hFCMR, clone 1E4 mouse IgG2bκ ) mAb was from Abnova (Taiwan). 
IgM from human serum, human serum from AB male, and lectin from Phaseolus vulgaris (phytohemagglutinin; 
PHA) were all from Sigma-Aldrich. Biotinylated Sambucus Nigra Lectin (SNA) was from Vector Laboratories, 
and biotinylated F(ab’)2 anti-human IgM was from Jackson ImmunoResearch. The structure, function and puri-
fication of domain swapped antibodies have been described previously16–18.
Cells. GFP+ hFCMR cDNA-transfected and untransfected mouse BW5147 T cells were generated as previ-
ously described1. Cells were cultured in RPMI 1640 supplemented with 2 mM L-glutamine, 10% FBS, 50 mM 
2-mercaptoethanol, 100 U/ml penicillin and 100 μ g/ml streptavidin at 37 °C and 5% CO2, with the addition of 
1 μ g/ml puromyosin to culture medium for the hFCMR cDNA-transfected cells. Buffy coats from blood of healthy 
individuals were obtained from the National Health Service (NHS) Blood and Transplant Service. Full informed 
consent and ethical approval for use of human PBMCs was obtained from the Liverpool School of Tropical 
Medicine ethics committee (reference number 11.92). Consent forms for all volunteer-related human use proce-
dures, such as purifying human PBMCs, are in accordance with the policies established by the institutional review 
board at LSTM under license 12548 granted by the Human Tissues Authority. Peripheral blood mononuclear cells 
(PBMCs) were isolated by Ficoll-Paque gradient centrifugation using Lymphoprep (Axis-Shield, Norway) and 
washed twice in RPMI/10% FBS.
Glycan analysis. Glycans were removed from hIgM using Peptide-N-Glycosidase F (PNGase F) and α 
2–3,6,8 neuraminidase according to the manufacturer’s protocol (New England Biolabs). Briefly, 50 μ g of hIgM 
(Sigma-Aldrich) was incubated overnight at 37 °C with the appropriate endoglycosidase and buffers as described 
previously39. Solutions of hIgM and buffer alone were used as controls (non-treated IgM). To determine the suc-
cess of endoglycosidase treatment, 5 μ g of treated or non-treated IgM was separated by 10% SDS-PAGE under 
reducing and non-reducing conditions, followed by staining with Coomassie Brilliant Blue R250 or immunoblot-
ted with SNA or anti-human IgM (to determine the extent of sialylation and protein loading respectively).
Molecular dynamic simulations. The atomic model of pentameric hIgM was described previously27. The 
on-line server, Phyre2, was used to identify regions within hFCMR that exhibit high homology to proteins with 
known structure and then generate homology models of these regions based on these known structures28,29. In 
this way, two regions of hFCMR could be modeled with high confidence. One region is homologous (with ~70% 
confidence) to the transmembrane domain of the ErbB2 receptor tyrosine kinase30. The other region is homol-
ogous (with 99.6% confidence) to the extracellular, Ig-like domain of IREM-148. Since Ig-like domains of other 
receptors that bind hIgM are known to directly contact hIgM, we further investigated interactions between this 
domain and hIgM. In particular, we focused on three loops at one end of this Ig-like domain, the complemen-
tarity determining regions (CDR1, CDR2 and CDR3), since these loops directly contact IgM in the other IgM 
receptors35.
We first evaluated two models, Cμ 2/Cμ 4/hFCMR and Cμ 3/Cμ 4/hFCMR, using all-atom molecular dynam-
ics simulations to determine which of the two interactions with hFCMR were energetically more favorable. In 
particular, we manually placed the Ig-like domain of hFCMR within the Cμ 2/Cμ 4 interface of an IgM monomer 
(extracted from the pentameric IgM model) or within the Cμ 3/Cμ 4 interfaces of two neighboring hIgM mono-
mers of the IgM pentamer (Fig. S4). The interaction of hFCMR with the hIgM monomer and dimer were studied, 
instead of the whole hIgM pentamer, to reduce computational load. The location of this hFCMR domain was cho-
sen such that the CDRs were within close contact with both Cμ domains and that there were favorable contacts 
between hydrophobic and charged residues on the surfaces of both Cμ and hFCMR domains. For these simula-
tions, we held fixed the positions of residues within the Cμ domains far from the interaction with hFCMR so that 
the overall structure of the hIgM proteins would be similar to that in the present pentameric hIgM model27. For 
the Cμ 2/Cμ 4/hFCMR model, the regions held fixed were residues 150 to 165 in Cμ 2 domain and residues 322 
to 330, 385 to 395, and 415 to 425 in one Cμ 4 domain, and residues 338 to 348 and 400 to 410 in the other Cμ 4 
domain. For the Cμ 3/Cμ 4/hFCMR model, the regions held fixed were residues 231 to 240, 290 to 300, 323 to 330 
and 415 to 425. None of the residues within the hFCMR domain were held fixed. Both models were then solvated 
in TIP3 water in 0.15 M NaCl and minimized and equilibrated using VMD/NAMD and the CHARMM 27 force 
field49–51. The time step was set at 2 fs, and Langevin dynamics were employed to maintain a constant temperature 
of 310 K. Equilibration of the systems was evaluated by monitoring the root mean square deviation of the protein 
backbone. We evaluated the strength of the interaction based on the number of residues within close contact (3 Å) 
of the binding partner and the extent of buried solvent-accessible surface area, measured using VMD. Finally, we 
performed equilibration simulations of the interaction between hFCMR and the Cμ 2/Cμ 4 region with an intact, 
unconstrained hIgM Fc monomer. We confirmed that the structure of the hIgM Fc monomer at the end of these 
simulations was compatible with the original model of the pentameric IgM structure.
IgM binding and internalization. A panel of domain-swap Abs, in which the domains of IgA were replaced 
with domains of IgM have been described previously16–18. These were incubated with hFCMR-transfected cells 
for 1 hr on ice, washed extensively with ice-cold media and labeled with F(ab’)2-anti-human lambda-RPE prior to 
flow cytometry analysis (BD LSRII).
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The ability of hFCMR to internalize hIgM was investigated using a previously described protocol with minor 
modifications6. Briefly, hFCMR-transfected cells or PBMCs were incubated for 1 hr on ice with media alone or 
media supplemented with 15 μ g/ml hIgM or 10% human serum. In some experiments, binding and internali-
zation of endoglycosidase-treated hIgM (15 μ g/ml) was also assessed, as was the binding and internalization of 
heat-aggregated hIgM (62 °C for 30 min)52,53. Cells were washed twice and then maintained on ice as a control 
for maximal binding or incubated at 37 °C to allow for receptor internalization. Internalization was halted by 
the addition of ice-cold media to cells and a brief incubation on ice. Cells were washed and labeled with F(ab’)2 
anti-human IgM-RPE and/or fluorescent antibodies against human CD3, CD4, CD8, CD19 and CD56 to deter-
mine IgM surface levels by flow cytometry.
Immunofluorescent microscopy. To determine IgM internalization by fluorescent microscopy, 1 × 105 
GFP+ hFCMR-transfected cells were cytospun onto slides following incubations at 37 °C (as above) and fixed in 
4% paraformaldehyde for 10 min at room temperature. Cells were blocked for 15 min in blocking buffer (PBS/5% 
goat serum), washed with PBS and labeled with F(ab’)2 anti-human IgM-RPE in PBS/1% BSA for 1 hr. Following 
immunostaining cells were washed twice, labeled with DAPI (ThermoScientific) for 5 min at room temperature, 
and coverslipped. Cell permeabilization was performed in some experiments to determine intracellular levels of 
IgM following incubations at 37 °C. For this, 0.1% saponin was added to the blocking and staining buffers. Images 
were acquired using a Zeiss Axioskop microscope using the 40x objective. Images were processed using Abode 
Photoshop using only level and contrast adjustment (without manipulating the gamma function). The same set-
tings were used for processing and analyzing the images.
Lymphocyte proliferation assays. PBMCs isolated from healthy donors were labeled with 1 μ M CellTrace 
Violet in accordance with the manufacturer’s instructions. Labeled cells (2 × 105 cells/well) were stimulated with 
various concentrations of hIgM or BSA pre-incubated with 5 μ g/ml PHA for 5d at 37 °C. Cells stimulated with 
PHA or hIgM/BSA alone were used as positive and negative controls, respectively. After 5d, cells were washed and 
labeled with anti-human CD4-Alexa Fluor®700 and anti-human CD8-FITC to determine cellular proliferation of 
gated lymphocytes by flow cytometry.
Statistical analysis. Statistical comparison between various groups was performed by Mann-Whitney 
comparisons, using the GraphPad Prism 6 software. Differences were determined to be significant when P vales 
were < 0.05.
Ethical approval. Buffy coats from blood of healthy individuals were obtained from the National Health 
Service (NHS) Blood and Transplant Service. Full informed consent and ethical approval for use of human 
PBMCs was obtained from the Liverpool School of Tropical Medicine ethics committee (reference number 
11.92). Consent forms for all volunteer-related human use procedures, such as purifying human PBMCs, are in 
accordance with the policies established by the institutional review board at LSTM under license 12548 granted 
by the Human Tissues Authority.
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